Anticancer Drugs 2022 Mar 23. Epub 2022 Mar 23.
Department of Respiratory and Critical Care Medicine, Shenzhen People's Hospital, The First Affiliated Hospital of Southern University of Science and Technology, The Second Clinical School of Jinan University, Shenzhen Municipal Institute of Respiratory Medicine, Shenzhen, Guangdong, China.
Treatment options for heavily treated anaplastic lymphona kinase (ALK)-positive nonsmall cell lung cancer (NSCLC) patients, who typically bear-resistant mechanisms to ALK tyrosine kinase inhibitors (TKIs), are usually limited to chemotherapy, which elicits limited clinical benefit and may incur severe toxicity. It is clinically relevant to explore other revenues for these patients. poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib are currently approved to treat BReast CAncer gene 1/2 (BRCA1/2)-mutated patients in a few tumor types. Read More